Share

October 2015; 2 (5) ArticleOpen Access

Effects of diazoxide in multiple sclerosis

A randomized, double-blind phase 2 clinical trial

Pablo Villoslada, Alex Rovira, Xavier Montalban, Rafael Arroyo, Friedemann Paul, Virginia Meca-Lallana, Cristina Ramo, Oscar Fernandez, Albert Saiz, Antonio Garcia-Merino, Lluís Ramió-Torrentà, Bonaventura Casanova, Celia Oreja-Guevara, Delicias Muñoz, Jose Enrique Martinez-Rodriguez, Eckart Lensch, Jose Maria Prieto, Sven G. Meuth, Xavier Nuñez, Clara Campás, Marco Pugliese, For the NeuroAdvan study
First published September 10, 2015, DOI: https://doi.org/10.1212/NXI.0000000000000147
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1015

Share

Article Information

vol. 2 no. 5 e147
DOI: 
https://doi.org/10.1212/NXI.0000000000000147
PubMed: 
26405686
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received March 17, 2015
  • Accepted in final form July 15, 2015
  • First Published September 10, 2015.
Copyright & Usage: 
© 2015 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. Pablo Villoslada, MD,
    2. Alex Rovira, MD,
    3. Xavier Montalban, MD,
    4. Rafael Arroyo, MD,
    5. Friedemann Paul, MD,
    6. Virginia Meca-Lallana, MD,
    7. Cristina Ramo, MD,
    8. Oscar Fernandez, MD,
    9. Albert Saiz, MD,
    10. Antonio Garcia-Merino, MD,
    11. Lluís Ramió-Torrentà, MD,
    12. Bonaventura Casanova, MD,
    13. Celia Oreja-Guevara, MD,
    14. Delicias Muñoz, MD,
    15. Jose Enrique Martinez-Rodriguez, MD,
    16. Eckart Lensch, MD,
    17. Jose Maria Prieto, MD,
    18. Sven G. Meuth, MD, PhD,
    19. Xavier Nuñez, PhD,
    20. Clara Campás, PhD,
    21. Marco Pugliese, PhD;
    22. For the NeuroAdvan study
  1. Pablo Villoslada, MD,
    2. Scientific Advisory Boards:

    1. Roche, Novartis, Neurotec Farma, Bionure Farma; Consultant: Novartis, Roche, TFS, Heidelberg Engineering, MedImmune, Digna Biotec, Neurotec Pharma

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Novartis, Roche

    Editorial Boards:

    1. PloSONE, Academic editor, 2011-- Neurology & Therapy, editorial board, 2014Curr There Op Neurol, editorial board 2014 Mult Scl & Demyel Dis, editorial board 2015

    Patents:

    1. 1. Methyltioadenosine for the treatment of MS 2. Agonistic neurotrophic compounds for the treatment of brain Diseases 3. Gene signature pattern as a biomarker for MS4. Algorithm for quantifying fractal dimension in brain MRI

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. unrestricted grants from Novartis, Roche and Genzyme

    Research Support, Government Entities:

    1. Instituto de Salud Carlos III, European Commission, National MS Society

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Fundacion Maraton TV3

    Stock/Stock Options/Board of Directors Compensation:

    1. Bionure Pharma

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Alex Rovira, MD,
    3. Scientific Advisory Boards:

    1. (1) Novartis, (2) Biogen, (3) Genzyme

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1) Bayer, (2) Teva Pharmaceutical Industries Ltd, (3) Genzyme, (4) Bracco, (5) Merck-Serono, (6) Biogen Idec, (7) OLEA

    Editorial Boards:

    1. Editorial boards of: (1) Am J Neuroradiol. Editorial board member, 2008 at present; (2) Neuroradiology. Editorial board member, 2006 at present;

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. (1) Bayer, (2) Teva Pharmaceutical Industries Ltd, (3) Genzyme, (4) Bracco, (5) Merck-Serono, (6) Biogen Idec, (7) OLEA

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Xavier Montalban, MD,
    4. Scientific Advisory Boards:

    1. (1) Novartis, (2) Teva Pharmaceutical, (3) Merck, (4) Biogen, (5) Bayer, (6) Almirall, (7) Actelion, (8) Genzyme, (9) Octapharma, (10) Receptos, (11) Roche, (12) Sanofi, (13) Trophos

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Travel to scientific meetings: (1) Novartis, (2) Teva Pharmaceutical, (3) Merck, (4) Biogen, (5) Bayer, (6) Almirall, (7) Actelion, (8) Genzyme, (9) Octapharma, (10) Receptos, (11) Roche, (12) Sanofi, (13) Trophos

    Editorial Boards:

    1. Member of editorial boards: (1) Multiple Sclerosis, (2) Journal of Neurology, (3) The International MS Journal, (4) Revista Neurologia, (5) Therapeutic Advances in Neurological Disorders

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Novartis, (2) Teva Pharmaceutical, (3) Merck, (4) Biogen, (5) Bayer, (6) Almirall, (7) Actelion, (8) Genzyme, (9) Octapharma, (10) Receptos, (11) Roche, (12) Sanofi, (13) Trophos

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Vice President, Multiple Sclerosis Foundation of Barcelona (FEM)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Rafael Arroyo, MD,
    5. Scientific Advisory Boards:

    1. Teva, Biogen, Novartis, Merck-Serono, Roche, Bayer, Genzyme, Sanofi, Almirall

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Teva, Biogen, Novartis, Merck-Serono, Roche, Bayer, Genzyme, Sanofi, Almirall: speaker honoraria

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Friedemann Paul, MD,
    6. Scientific Advisory Boards:

    1. Novartis OCTIMS study steering committee MedImmune steering committee

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. speaker honoraria and travel grants from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, and Merck Serono

    Editorial Boards:

    1. Academic Editor, PLoS ONE Associate Editor, Neurology Neuroimmunology and Neuroinflammation

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. consultancies for SanofiGenzyme, BiogenIdec, MedImmune

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Research support from from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, and Merck Serono

    Research Support, Government Entities:

    1. German Research Council (DFG Exc 257), Werth Stiftung of the City of Cologne, German Ministry of Education and Research (BMBF Competence Network Multiple Sclerosis)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Arthur Arnstein Foundation Berlin, Guthy Jackson Charitable Foundation, National Multiple Sclerosis Society of the USA

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Virginia Meca-Lallana, MD,
    7. Scientific Advisory Boards:

    1. Roche

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Biogen Idec, Novartis, Merk, TEVA

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Cristina Ramo, MD,
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Travel funded by a commercial entity to attend conferences Honoraria for speaking engagements

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Biogen, Genzyme, Novartis, Almirall

    Research Support, Government Entities:

    1. Instituto de Salud Carlos III. Spain Fondo de Investigaciones Sanitarias (FIS). Spain

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Oscar Fernandez, MD,
    9. Scientific Advisory Boards:

    1. has received honoraria as consultant in advisory boards, and as chairmen or lecturer in meetings, and has also participated or participates at present in clinical trials and other research projects promoted by Biogen-Idec, Bayer-Schering; Merck-Serono, Teva, Novartis, Actelion, Almirall and Allergan.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. has received honoraria as consultant in advisory boards, and as chairmen or lecturer in meetings, and has also participated or participates at present in clinical trials and other research projects promoted by Biogen-Idec, Bayer-Schering; Merck-Serono, Teva, Novartis, Actelion, Almirall and Allergan.

    Editorial Boards:

    1. Revista de Multiple Sclerosis

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. has received honoraria as consultant in advisory boards, and as chairmen or lecturer in meetings, and has also participated or participates at present in clinical trials and other research projects promoted by Biogen-Idec, Bayer-Schering; Merck-Serono, Teva, Novartis, Actelion, Almirall and Allergan.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Albert Saiz, MD,
    10. Scientific Advisory Boards:

    1. (1) Biogen Idec, (2) Merck-Serono

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1) Bayer-Schering, (2) Merck-Serono, (3) Biogen Idec, (4) Sanofi-Aventis, (5) Teva Pharmaceutical Industries, (6) Novartis

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Bayer-Schering, (2) Merck-Serono, (3) Biogen-Idec, (4) Sanofi-Aventis, (5) Teva Pharmaceutical Industries, (6) Novartis

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Antonio Garcia-Merino, MD,
    11. Scientific Advisory Boards:

    1. Biogen, Idec, Novartis, Roche, Genzyme, Merck

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Biogen, Idec, Novartis, Almirall, Genzyme, Roche, Merck

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Research grants from Novartis and Biogen Idec

    Research Support, Government Entities:

    1. Research grant from FIS years 2012-15

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  11. Lluís Ramió-Torrentà, MD,
    12. Scientific Advisory Boards:

    1. (1) Biogen, (2) Roche, (3) Novartis, (4) TEVA

    Gifts:

    1. (1) Biogen, congresses, (2) Roche, congresses, (3) Novartis, congresses, (4) TEVA, congresses, (5) Bayer-Schering, congresses, (6) Merck-Serono, congresses, (7) Genzyme, congresses

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  12. Bonaventura Casanova, MD,
    13. Scientific Advisory Boards:

    1. Biogen-Idec, Cenzyme, TEVA, Novartis

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  13. Celia Oreja-Guevara, MD,
    14. Scientific Advisory Boards:

    1. Genzyme (1)

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1) Speaker honoraria by Biogen, Novartis, Teva, Genzyme

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  14. Delicias Muñoz, MD,
    15. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  15. Jose Enrique Martinez-Rodriguez, MD,
    16. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Consulting services to Roche and Bayer.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  16. Eckart Lensch, MD,
    17. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Bayer GmbH, speaker honorarium Merck Serono GmbH, speaker honorarium

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  17. Jose Maria Prieto, MD,
    18. Scientific Advisory Boards:

    1. Biogen, Novartis, Bayer, Merck-SERONO, Teva, Genzyme and Almirall

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Biogen, Novartis, Bayer, Merck-SERONO, Teva, Genzyme and Almirall

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Biogen, Novartis, Bayer, Merck-SERONO, Teva, Genzyme and Almirall

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  18. Sven G. Meuth, MD, PhD,
    19. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. PLoS One

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Sven G. Meuth (SGM) has received honoraria for lecturing and travel expenses for attending meetings and has received financial research support from Bayer, Bayer Schering, Biogen Idec, Genzyme, Merck Serono, MSD, Novartis, Novo Nordisk, Sanofi-Aventis and Teva.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  19. Xavier Nuñez, PhD,
    20. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  20. Clara Campás, PhD,
    21. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Advancell, Advanced In Vitro Cell Technologies, SA SME biomedicine company 2006 to 2014 Managing Director

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  21. Marco Pugliese, PhD;
    22. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  22. For the NeuroAdvan study
  1. From the Institut d' Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)—Hospital Clinic (P.V., A.S.), Barcelona, Spain; Unitat de RM (Servei de Radiologia) (A.R., X.M.), Departamento de Neurología-Neuroinmunología, Centro de Esclerosis Múltiple de Cataluña (Cemcat), Hospital Vall d'Hebron, Barcelona, Spain; Hospital Clinico San Carlos (R.A., C.O.-G.), Madrid, Spain; NeuroCure Clinical Research Center and Department of Neurology (F.P.), Charité University Medicine Berlin, Berlin, Germany; Hospital de La Princesa (V.M.-L.), Madrid, Spain; Hospital Germans Trias i Pujol (C.R.), Badalona, Spain; Hospital Regional Universitario (IBIMA) (O.F.), Malaga, Spain; Hospital Puerta de Hierro (A.G.-M.), Madrid, Spain; Hospital Universitari Dr Josep Trueta (L.R.-T.), IDIBGI, Girona, Spain; Hospital La Fe (B.C.), Valencia, Spain; Hospital Xeral-Cies (D.M.), Vigo, Spain; Hospital del Mar (J.E.M.-R.), Barcelona, Spain; Deutsche Klinik für Diagnostik (E.L.), Wiesbaden, Germany; Hospital Universitario Santiago de Compostela (J.M.P.), Spain; Department of Neurology (S.G.M.), University of Munster, Germany; TrialFormSupport (X.N.), Barcelona, Spain; Advancell, Advanced In Vitro Cell Technologies, S.A (C.C.), Barcelona, Spain; and Neurotec Pharma S.L (M.P.), Barcelona, Spain.
  1. Correspondence to Dr. Villoslada: pvilloslada{at}clinic.ub.es
View Full Text

Article usage

Article usage: September 2015 to February 2023

AbstractFullPdfSource
Sep 201531151833Highwire
Sep 201504118pmc
Oct 20153257429Highwire
Oct 2015013261pmc
Nov 2015811618Highwire
Nov 201505428pmc
Dec 2015481311Highwire
Dec 20150276pmc
Jan 2016452213Highwire
Jan 201602112pmc
Feb 201667914Highwire
Feb 20160266pmc
Mar 2016701817Highwire
Mar 20160206pmc
Apr 2016501315Highwire
Apr 20160208pmc
May 2016351111Highwire
May 201601410pmc
Jun 201646610Highwire
Jun 20160103pmc
Jul 2016372013Highwire
Jul 20160197pmc
Aug 201631199Highwire
Aug 20160100pmc
Sep 20162384Highwire
Sep 20160114pmc
Oct 201634514Highwire
Oct 20160263pmc
Nov 20161218Highwire
Nov 20160113pmc
Dec 20161847Highwire
Dec 20160205pmc
Jan 201731105Highwire
Jan 2017063pmc
Feb 20171321Highwire
Feb 20170134pmc
Mar 20171653Highwire
Mar 2017090pmc
Apr 20171324Highwire
Apr 201741515pmc
May 20172155Highwire
May 201751317pmc
Jun 20171112Highwire
Jun 20170712pmc
Jul 2017931Highwire
Jul 20172810pmc
Aug 2017943Highwire
Aug 201701215pmc
Sep 2017530Highwire
Sep 20174127pmc
Oct 20171565Highwire
Oct 2017286pmc
Nov 20172085Highwire
Nov 201721620pmc
Dec 20171166Highwire
Jan 20181133Highwire
Feb 20180249Highwire
Mar 20180272Highwire
Apr 20180473Highwire
Apr 2018056pmc
May 20180814Highwire
Jun 20180795Highwire
Jun 201801010pmc
Jul 20180725Highwire
Aug 20181282Highwire
Aug 2018177pmc
Sep 20180285Highwire
Oct 20181357Highwire
Nov 20180814Highwire
Dec 201801336Highwire
Jan 20191992Highwire
Feb 2019410810Highwire
Mar 20190371Highwire
Apr 2019184Highwire
May 2019122911Highwire
Jun 201921413Highwire
Jul 20192118Highwire
Aug 20192179Highwire
Sep 20191105Highwire
Oct 20194197Highwire
Nov 20192197Highwire
Dec 20192217Highwire
Jan 20200173Highwire
Feb 20202195Highwire
Mar 20200127Highwire
Apr 20201194Highwire
May 20200334Highwire
Jun 20200121Highwire
Jul 20201121Highwire
Aug 20201213Highwire
Sep 20204347Highwire
Oct 20203235Highwire
Nov 20201168Highwire
Dec 20202288Highwire
Jan 20211316Highwire
Feb 202113013Highwire
Mar 20210144Highwire
Apr 20211134Highwire
May 202122211Highwire
Jun 20213175Highwire
Jul 20215138Highwire
Aug 20212154Highwire
Sep 20211166Highwire
Oct 202132824Highwire
Nov 202113621Highwire
Dec 20211218Highwire
Jan 20220185Highwire
Feb 20222308Highwire
Mar 202211811Highwire
Apr 202202011Highwire
May 20221179Highwire
Jun 202221412Highwire
Jul 20221306Highwire
Aug 20228246Highwire
Sep 202233413Highwire
Oct 20222299Highwire
Nov 202274819Highwire
Dec 20221206Highwire
Jan 20234317Highwire
Feb 20233226Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Topics Discussed

Alert Me

Recommended articles